The CDC has reported that the monovalent mRNA vaccine is 76% effective at preventing COVID-19-related invasive mechanical ventilation and death up to 6 months after the last dose, and 56% effective for at least…
Continue Reading
By Shania Kennedy April 25, 2023 – Moderna and IBM announced a partnership to leverage novel technologies, such as artificial intelligence (AI) and quantum computing, to accelerate messenger RNA (mRNA) research.
Quantum computing is a subset…
Researchers at MIT have developed lipid nanoparticles that are highly efficient at delivering mRNA therapies to lung cells. Getting therapeutic agents into the lungs can be challenging, but there are a variety of medical…
Continue Reading
Stephen Manley, CTO, DruvaThe greatest innovation in healthcare in the last twenty years is something that connects us all… data. At any given moment, healthcare facilities, hospitals and more rely on data to operate…
Continue Reading
In todays fast-paced world, it is easy to miss out on important information, especially if you are trying to keep up with a lot of different sources. That is where the daily digest comes in – it is a tool that compiles all the posts created on the previous day, providing you with a convenient summary of everything that happened so you can stay informed, educated, and engaged with the Digital Health world around you.
Continue Reading
What You Should Know:– A nationwide U.S. study of more than 893,000 adults provides solid evidence confirming that mRNA booster immunizations extend protection against moderate and severe COVID for four to five months. – These…
Continue Reading
Epstein-Barr is among the most common viruses, but no vaccines are available to prevent its infection. Merck is joining the pursuit for a vaccine by striking a deal with Opko Health, paying $50 million…
Continue Reading
Moderna’s ambitions in messenger RNA technology include therapies that do their editing work inside the patient. To that end, the biotech company is starting an R&D collaboration with a division of ElevateBio that brings…
Continue Reading
A Moderna messenger RNA vaccine for influenza now has preliminary data from a pivotal study showing the shot prompted a strong immune response to the more common strains of the virus but fell short against less common strains.
The results reported Thursday are from one of two pivotal studies for the Moderna vaccine, mRNA-1010, which is assessing the shot for safety and immune response. A separate Phase 3 study is evaluating the shot for efficacy. Results from that study could come as early as next month. Moderna’s vaccine encodes hemagglutinin, a protein on the surface of the influenza virus that is also…
